Top

European Journal of Medical Research

Published in:

01-12-2020 | Ciprofloxacin | Research

A mechanistic approach to prove the efficacy of combination therapy against New Delhi metallo-β-lactamases producing bacterial strain: a molecular and biochemical approach

Authors: Lubna Maryam, Abid Ali, Shamsi Khalid, Asad U. Khan

Published in: European Journal of Medical Research | Issue 1/2020

Abstract

Background

NDM-1 is a novel broad-spectrum metallo-β-lactamase with the capability to grant resistance to almost all β-lactam antibiotics. Its widespread dissemination made treatment options a major challenge to combat, causing threat to public health worldwide. Due to antibiotic resistance problems, development of effective therapeutics for infections caused by NDM-1 producing strains is urgently required. Since combination therapies are proved to be effective in many cases, this study was initiated to put forward novel effective antibiotics combinations for fighting infections caused by NDM-1 producing strains.

Methods

Streptomycin and amikacin combination and streptomycin and ciprofloxacin combination were tested by checkerboard assay. NDM-1 protein/enzyme was then expressed and purified to carry out enzyme kinetics study, CD and fluorescence spectroscopic studies.

Results

Streptomycin and amikacin combination and streptomycin and ciprofloxacin combination showed synergistic effect towards NDM-1 producing bacterial strains as shown by FICI results. NDM-1 producing bacterial cells were expressed and purified to obtain protein as the source of enzyme. When NDM-1 enzyme was treated with streptomycin along with amikacin, the efficiency of enzyme was decreased by 49.37% and when the enzyme was treated with streptomycin along with ciprofloxacin, the efficiency of enzyme was decreased by 29.66% as revealed by enzyme kinetic studies. Due to binding of streptomycin and amikacin in combination and streptomycin and ciprofloxacin in combination, conformational changes in the secondary structure of NDM-1 enzyme were observed by CD spectroscopic studies. Antibiotics streptomycin and ciprofloxacin bind with NDM-1 through exothermic processes, whereas amikacin binds through an endothermic process. All three antibiotics bind spontaneously with an association constant of the order of 10⁴ M⁻¹ as revealed by fluorescence spectroscopic studies.

Conclusions

The therapeutic combination of streptomycin with amikacin and ciprofloxacin plays an important role in inhibiting NDM-1 producing bacterial strains. Therefore, these combinations can be used as effective future therapeutic candidates against NDM-1 producing bacterial cells.

Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597–602. https://doi.org/10.1016/s1473-3099(10)70143-2.CrossRefPubMedPubMedCentral

Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20(3):440–58.CrossRef

Raghunath D. New metallo β-lactamase NDM-1. Indian J Med Res. 2010;132(5):478.PubMedPubMedCentral

Kaase M, Nordmann P, Wichelhaus TA, Gatermann SG, Bonnin RA, Poirel L. NDM-2 carbapenemase in Acinetobacter baumannii from Egypt. J Antimicrob Chemother. 2011;66(6):1260–2. https://doi.org/10.1093/jac/dkr135.CrossRefPubMed

Khan AU, Maryam L, Zarrilli R. Structure, genetics and worldwide spread of New Delhi metallo-β-lactamase (NDM): a threat to public health. BMC Microbiol. 2017;17(1):101. https://doi.org/10.1186/s12866-017-1012-8.CrossRefPubMedPubMedCentral

Kummana C, Yuen K. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs. 1994;47:902–13.CrossRef

Pitiriga V, Dimitroulia E, Saroglou G, Tsakris A. The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role? Exp Rev Anti Infect Ther. 2017;15(10):947–54. https://doi.org/10.1080/14787210.2017.1382355.CrossRef

Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999;43(4):727–37.CrossRef

Rodríguez-Avial I, Pena I, Picazo JJ, Rodríguez-Avial C, Culebras E. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Int J Antimicrob Agents. 2015;46(6):616–21. https://doi.org/10.1016/j.ijantimicag.2015.07.021.CrossRefPubMed

10.

King DE, Malone R, Lilley SH. New classification and update on the quinolone antibiotics. Am Fam Physician. 2000;61(9):2741–8.PubMed

11.

Heeb S, Fletcher MP, Chhabra SR, Diggle SP, Williams P, Cámara M. Quinolones: from antibiotics to autoinducers. FEMS Microbiol Rev. 2011;35(2):247–74. https://doi.org/10.1111/j.1574-6976.2010.00247.x.CrossRefPubMed

12.

Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001;7(2):337.CrossRef

13.

Berdal JE, Skra I, Mowinckel P, Gulbrandsen P, Bjørnholt JV. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin Microbiol Infect. 2005;11(10):843–5.CrossRef

14.

Liu H, Mulholland SG. Appropriate antibiotic treatment of genitourinary infections in hospitalized patients. Am J Med. 2005;118(7):14–20.CrossRef

15.

Maryam L, Khan AU. A mechanism of synergistic effect of streptomycin and cefotaxime on CTX-M-15 type β-lactamase producing strain of E. cloacae: a first report. Front Microbiol. 2016;7:2007. https://doi.org/10.3389/fmicb.2016.02007.CrossRefPubMedPubMedCentral

16.

Maryam L, Khan AU. Synergistic effect of doripenem and cefotaxime to inhibit CTX-M-15 type β-lactamases: biophysical and microbiological views. Front Pharmacol. 2017;8:449. https://doi.org/10.3389/fphar.2017.00449.CrossRefPubMedPubMedCentral

17.

Maryam L, Khan AU. Combination of aztreonam and cefotaxime against CTX-M-15 type β-lactamases: a mechanism based effective therapeutic approach. Int J Biol Macromol. 2018;116:1186–95. https://doi.org/10.1016/j.ijbiomac.2018.05.153.CrossRefPubMed

18.

Maryam L, Khalid S, Ali A, Khan AU. Synergistic effect of doripenem in combination with cefoxitin and tetracycline in inhibiting NDM-1 producing bacteria. Future Microbiol. 2019;14:671–89. https://doi.org/10.2217/fmb-2019-0032.CrossRefPubMed

19.

Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450–70. https://doi.org/10.1128/CMR.05041-11.CrossRefPubMedPubMedCentral

20.

Craig WA. Optimizing aminoglycoside use. Crit Care Clin. 2011;27(1):107–21. https://doi.org/10.1016/j.ccc.2010.11.006.CrossRefPubMed

21.

Lemaître N, Ricard I, Pradel E, Foligné B, Courcol R, Simonet M, Sebbane F. Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague. PLoS ONE. 2012;7(12):e52503. https://doi.org/10.1371/journal.pone.0052503.CrossRefPubMedPubMedCentral

22.

Ali A, Azam MW, Khan AU. Non-active site mutation (Q123A) in New Delhi metallo-β-lactamase (NDM-1) enhanced its enzyme activity. Int J Biol Macromol. 2018;112:1272–7. https://doi.org/10.1016/j.ijbiomac.2018.02.091.CrossRefPubMed

23.

Shen B, Yu Y, Chen H, Cao X, Lao X, Fang Y, Shi Y, Chen J, Zheng H. Inhibitor discovery of full-length New Delhi metallo-β-lactamase-1 (NDM-1). PLoS ONE. 2013;8(5):e62955. https://doi.org/10.1371/journal.pone.0062955.CrossRefPubMedPubMedCentral

24.

Khan AU, Rehman MT. Role of non-active-site residue Trp-93 in the function and stability of New Delhi metallo-β-lactamase 1. Antimicrob Agents Chemother. 2016;60(1):356–60. https://doi.org/10.1128/AAC.01194-15.CrossRefPubMed

25.

Wayne PA. Performance standards for antimicrobial susceptibility testing: 21st informational supplement. Clinical and Laboratory Standards Institute. 2011; M100-S21.

26.

Hasan S, Ali SZ, Khan AU. Novel combinations of antibiotics to inhibit extended-spectrum β-lactamase and metallo-β-lactamase producers in vitro: a synergistic approach. Future Microbiol. 2013;8(7):939–44. https://doi.org/10.2217/fmb.13.54.CrossRefPubMed

27.

Galleni M, Franceschini N, Quinting B, Fattorini L, Orefici G, Oratore A, Frère JM, Amicosante G. Use of the chromosomal class A beta-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory beta-lactam compounds. Antimicrob Agents Chemother. 1994;38(7):1608–14.CrossRef

28.

Ishtikhar M, Usmani SS, Gull N, Badr G, Mahmoud MH, Khan RH. Inhibitory effect of copper nanoparticles on rosin modified surfactant induced aggregation of lysozyme. Int J Biol Macromol. 2015;78:379–88. https://doi.org/10.1016/j.ijbiomac.2015.03.069.CrossRefPubMed

29.

Maryam L, Khan AU. Structural insight into mode of binding of Meropenem to CTX-M-15 type β-lactamase. Int J Biol Macromol. 2017;96:78–86. https://doi.org/10.1016/j.ijbiomac.2016.12.032.CrossRefPubMed

30.

Ali A, Danishuddin ML, Srivastava G, Sharma A, Khan AU. Designing of inhibitors against CTX-M-15 type β-lactamase: potential drug candidate against β-lactamases-producing multi-drug-resistant bacteria. J Biomol Struct Dyn. 2018;36(7):1806–21. https://doi.org/10.1080/07391102.2017.1335434.CrossRefPubMed

31.

Maryam L, Sharma A, Azam MW, Khan SN, Khan AU. Understanding the mode of binding mechanism of doripenem to human serum albumin: spectroscopic and molecular docking approaches. J Mol Recognit. 2018. https://doi.org/10.1002/jmr.2710.CrossRefPubMed

32.

Alam MF, Laskar AA, Maryam L, Younus H. Activation of human salivary aldehyde dehydrogenase by sulforaphane: mechanism and significance. PLoS ONE. 2016;11(12):e0168463. https://doi.org/10.1371/journal.pone.0168463.CrossRefPubMedPubMedCentral

33.

Kang J, Liu Y, Xie MX, Li S, Jiang M, Wang YD. Interactions of human serum albumin with chlorogenic acid and ferulic acid. Biochem Biophys Acta. 2004;1674(2):205–14.CrossRef

34.

Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8(6):423. https://doi.org/10.1038/nrmicro2333.CrossRefPubMedPubMedCentral

35.

O’Callaghan CH, Morris A, Kirby SM, Shingler AH. Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972;1(4):283–8.CrossRef

36.

Croney JC, Jameson DM, Learmonth RP. Fluorescence spectroscopy in biochemistry: teaching basic principles with visual demonstrations. Biochem Mol Biol Educ. 2001;29(2):60–5.CrossRef

37.

Möller M, Denicola A. Protein tryptophan accessibility studied by fluorescence quenching. Biochem Mol Biol Educ. 2002;30(3):175–8.CrossRef

38.

Eftink MR, Ghiron CA. Exposure of tryptophanyl residues in proteins. Quantitative determination by fluorescence quenching studies. Biochemistry. 1976;15(3):672–80.CrossRef

39.

Lakowicz JR. Principles of frequency-domain fluorescence spectroscopy and applications to cell membranes. In: Fluorescence studies on biological membranes. Boston: Springer; 1988, p. 89–126.

40.

Rehman MT, Shamsi H, Khan AU. Insight into the binding mechanism of imipenem to human serum albumin by spectroscopic and computational approaches. Mol Pharm. 2014;11(6):1785–97. https://doi.org/10.1021/mp500116c.CrossRefPubMed

41.

Maryam L, Khalid S, Ali A, Khan AU. Significant role of Asn-247 and Arg-64 residues in close proximity of the active site in maintaining the catalytic function of CTX-M-15 type β-lactamase. RSC Adv. 2019;9(10):5325–37.CrossRef

42.

Michalak K, Sobolewska-Włodarczyk A, Włodarczyk M, Sobolewska J, Woźniak P, Sobolewski B. Treatment of the fluoroquinolone-associated disability: the pathobiochemical implications. Oxid Med Cell Longev. 2017;2017:8023935.PubMedPubMedCentral

Title: A mechanistic approach to prove the efficacy of combination therapy against New Delhi metallo-β-lactamases producing bacterial strain: a molecular and biochemical approach
Authors: Lubna Maryam
Abid Ali
Shamsi Khalid
Asad U. Khan
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Ciprofloxacin
Amikacin
Aminoglycoside
Antibiotic
Published in: European Journal of Medical Research / Issue 1/2020
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-020-00418-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A mechanistic approach to prove the efficacy of combination therapy against New Delhi metallo-β-lactamases producing bacterial strain: a molecular and biochemical approach

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal–fetal transmission: a systematic review and meta-analysis

Comparative efficacy of treatments for patients with knee osteoarthritis: a network meta-analysis

Detection of arrhythmia using an implantable cardiac monitor following a cryptogenic stroke: a single-center observational study

Impact of lockdown on COVID-19 prevalence and mortality during 2020 pandemic: observational analysis of 27 countries

Laparoscopic-based perivascular renal sympathetic nerve denervation: a feasibility study in a porcine model

Transitional fracture of the distal radius: a rare injury in adolescent athletes. Case series and literature review